Umbralisib (Ukoniq): Drug recall because increased risk of patient death
May 08, 2022 – Umbralisib (Ukoniq) is a medication for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL). Umbralisib (Ukoniq) inhibits multiple kinases. In biochemical and cell-based assays, Umbralisib inhibited PI3Kδ and casein kinase CK1ε. PI3Kδ is expressed in …
Umbralisib (Ukoniq): Drug recall because increased risk of patient death Read more »